



FIFTY YEARS OF THE JOURNAL LIBRI ONCOLOGICI

We are proud to present the 50th volume of the Libri Oncologici, Croatian Journal of Oncology, a professional and scientific oncological journal published by the University Hospital for Tumors, Sestre milosrdnice University Hospital Center in Zagreb.

The journal was launched in 1972 by the publishers: Central Institute for Tumors and Allied Diseases (the former official name of University Hospital for Tumors in Zagreb), the League Against Cancer of the Socialist Republic of Croatia, the Cancer Section of the Croatian Medical Association and the PLIVA Chemical and Pharmaceutical Company. The journal was published four times a year initially and had regional significance. In 1992, the journal changed its publishing frequency (three times a year), format, and editorial board. The papers have since been published in English only, covering all experimental, translational, and clinical oncology areas. Since 1997, the University Hospital for Tumors has been the only publisher. In 2010, after the merger of the University Hospital for Tumors with the Sestre milosrdnice University Hospital Center, the publishing of Libri Oncologici had continued. The editors-in-chief were: Ivo Padovan (1972-73), Predrag Keros (1974-91), Krsto Kolarić (1992-95), Marko Turić (1996-2010), Danko Velimir Vrdoljak (2011-2020) and Ivan Milas (2020-).

The articles are peer-reviewed, and the reviewers are both Croatian and foreign. Libri Oncologici is an open-access journal. The journal's content is available in its entirety, free of charge. Users may copy and distribute the material and modify, redesign, or rework it as long as they cite the original appropriately (CC-BY-NC-ND).

So far, 49 volumes, 118 issues, 1198 articles, and 14 supplements – books of abstracts from various congresses and symposia have been published. Croatian science database Hrčak included Libri Oncologici in 2017. Libri Oncologici is in SCOPUS, EMBASE/Excerpta Medica, Index Copernicus, DOAJ, CrossRef, Scilit, ResGate...

Oncology is one of the most dynamic and fastest-growing areas of medicine. Libri Oncologici closely followed trends in oncology for the past 50. From the limited options of oncological care to the challenges of personalized therapy. Although significant progress has been made in screening methods, early diagnosis, and treatment options, malignant diseases regrettably still hold a high second place in mortality. There is a decrease in mortality in individual sites. However, there is also an increase in incidence for most leading tumor sites.

The scope of Libri Oncology will remain focused on oncology in all its areas. A priority in publication will stay on the scientific articles in prevention and early diagnosis, treatment of malignant diseases using all available modalities, monitoring of treatment outcomes, new genetic and molecular markers, and the results of targeted therapies. We plan to introduce socio-economic analysis, study protocols, and patient-related outcomes as categories.

Libri Oncologici aims to be a journal where clinicians will continue to find relevant articles and choose to publish them.

Ivan Milas
Editor-in-Chief